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The  virtuous  circle  of  building  evidence  in
abdominal  interventional  radiologyThis  issue  of  Diagnostic  and  Interventional  Imaging  is  entirely  devoted  to  interventional
imaging  of  the  abdomen.  This  is  clearly  a  strong  indicator  of  a  growing  interest  in  the
radiological  and  medical  communities  for  minimally  invasive  therapies.  It  is  interesting
to  note  that  these  therapies  are  not  new,  and  most  of  them  were  developed  by  glorious
French  pioneers  such  as  Professor  Alain  Roche  and  Professor  Claude  Lherminé  among  many
others.  Thanks  to  them,  since  the  early  1980s,  imaging  has  been  moving  from  diagnosis
to  therapy  and  a  common  language,  a  common  education  beyond  imaging  is  needed  in
order  to  better  communicate  and  collaborate  with  physicians  from  other  specialties.  As
radiologists,  we  need  a  deep  knowledge  regarding  voxels,  signal,  functional  imaging,  but
as  therapists  we  need  to  know  about  time  to  progression  (TTP),  overall  survival  (OS)  and
Easter  Cooperative  Oncology  Group  (ECOG)  performance  status.  As  a  consequence,  we
must  now  have  a  deep  knowledge  of  imaging  at  large  and  be  able  to  evaluate  OS  curves  as
well  as  MR  images.
Pioneers  in  the  ﬁeld  of  interventional  imaging  early  understood  the  need  for  building
evidence  through  proper  research  and  the  need  for  collaboration  with  other  specialists  like
hepatologists,  gastroenterologists  and  oncologists  who  have  a  well  acknowledged  rigorous
approach  to  medical  practices.  This  has  been  a  strong  background  for  the  next  generation
and  also  for  the  industry,  which  supports  actively  research  in  this  ﬁeld.  Radioembolization
with Y90,  as  explained  in  this  issue  by  Vesselle  et  al.,  is  a  very  good  example  of  this  virtuous
circle  [1].  The  small  to  mid-size  companies  that  handle  these  radioelements  have  under-
stood  very  early  the  need  of  randomized  trials  in  the  era  of  evidence-based  medicine.
In  this  regard,  the  results  of  the  SIRFLOX  trial  designed  to  evaluate  whether  FOLFOX
chemotherapy  in  combination  with  selective  internal  radiation  therapy  is  more  effective
than  chemotherapy  alone  will  be  presented  this  year  at  the  ASCO  meeting  in  Chicago.  Sim-
ilarly,  the  French  SARAH  trial  was  designed  to  compare  Sorafenib  versus  radioembolization
in  advanced  hepatocellular  carcinoma  and  has  ﬁnished  the  recruitment  phase.  These  two
comparative  trials  illustrate  that  high-quality  medical  evidence  changes  medical  practice
and  will  provide  for  adequate  reimbursement  of  procedures  and  devices  and  will  then
allow  further  ﬁnancial  investment  in  research  and  product  development.  This  virtuous  cir-
cle  helps  the  development  of  new  techniques  [2]  or  new  devices  in  partnership  with  the
industry  [3].
http://dx.doi.org/10.1016/j.diii.2015.05.003
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This  issue  of  Diagnostic  and  Interventional  Imaging  is
learly  the  sign  of  the  fantastic  enthusiasm  of  our  young
olleagues.  It  illustrates  that  our  treatments  are  sometimes
artnered  with  other  specialties  as  reported  by  Oldrini  et  al.
4],  with  radiotherapists  for  placement  of  ﬁducial  markers
efore  stereotactic  body  radiation  therapy,  but  often  com-
etitors  of  surgery  as  presented  by  Seror  [5]  and  de  Baere
t  al.  for  ablation  [6].  In  order  to  be  part  of  recommended
edical  practice,  interventional  radiologists  must  produce
igh-quality  research  to  better  defend,  develop,  promote
ur  practice,  discover  new  techniques  and  explore  new  hori-
ons,  which  are  the  future  of  our  specialty.
Research  is  not  an  option,  it  is  a  vital  need!
eferences
1] Vesselle G, Petit I, Boucebci S, Rocher T, Velasco S, Tasu JP.
Radioembolization with yttrium-90 microspheres work up: prac-
tical approach and literature review. Diagn Interv Imaging 2015.
2] Deschamps F, Farouil G, de Baere T. Percutaneous ablation of
bone tumors. Diagn Interv Imaging 2014;95:659—63.
3] Iannessi A, Marcy PY, Clatz O, Fillard P, Ayache N. Touchless intra-
operative display for interventional radiologist. Diagn Interv
Imaging 2014;95:333—7.Continuing  education  program:  editorial
4] Oldrini, Taste-George H, Renard-Oldrini S, Baumann AS, March-
esi V, Trouﬂéau P, et al. Implantation of ﬁducial markers in
the liver for stereotactic body radiation therapy: feasibility and
results. Diagn Interv Imaging 2015.
5] Seror O. Ablative therapies: how to choose the right method for
my patient? Diagn Interv Imaging 2015.
6] De Baere T, Tselikas L, Pearson E, Yevitch S, Boige V, Malka D,
et al. Interventional oncology for liver and lung metastases of
colorectal cancer: the current state of the art. Diagn Interv
Imaging 2015.
A.  Denys ∗
Service de radiologie et de radiologie
interventionnelle, CHUV Université de Lausanne,
rue du Bugnon, 1011 Lausanne, Switzerland
T.  de  Baere
Service d’imagerie interventionnelle, Institut
Gustave-Roussy, 114, rue Édouard-Vaillant, 94805
